HER2 Breast Cancer

Researchers will dissect topline results from the MARIANNE trial in an effort to understand why T-DM1 failed to triumph as a first-line treatment in the metastatic setting for patients with advanced HER2-positive breast cancer despite the promise of earlier findings.

Two HER2-targeting regimens anchored by T-DM1 failed to outperform the standard strategy in women with previously untreated advanced HER2-positive breast cancer, dealing a blow to efforts to move the drug into frontline settings.

William J. Gradishar, MD, discusses advances in the last year in the treatment of patients with HER2-positive breast cancer.

Frontline treatment with everolimus (Afinitor) combined with trastuzumab (Herceptin) and paclitaxel failed to delay disease progression versus trastuzumab and paclitaxel alone in patients with HER2-positive advanced breast cancer.

Women with HER2-positive breast cancer and high levels of stromal tumor-infiltrating lymphocytes (S-TILs) treated with chemotherapy alone had an 80% lower likelihood of disease recurrence compared to those with lower TIL counts.

Frontline treatment with neratinib and paclitaxel demonstrated similar ORR and PFS as trastuzumab and paclitaxel while lowering the incidence of CNS metastases in patients with locally recurrent or metastatic HER2-positive breast cancer.

Ruth M. O’Regan, MD, director, Translational Breast Cancer Research, professor, hematology and oncology, medical oncology, Winship Cancer Institute, Emory University, discusses the mechanism of action of trastuzumab.

The FDA has assigned a priority review designation to palbociclib in combination with letrozole as a frontline treatment for postmenopausal patients with ER-positive, HER2-negative advanced breast cancer.

Sandra M. Swain, MD, Medical Director of the Washington Cancer Institute at MedStar Washington Hospital Center, discusses results and key takeaways from the final overall survival (OS) analysis of the CLEOPATRA study.

Dual HER2 blockade with pertuzumab and trastuzumab plus chemotherapy for the treatment of HER2-positive metastatic breast cancer improved median overall survival (OS) by almost 16 months over standard first-line therapy.

HER2 blockade may enhance the duration of response to fulvestrant, according to researchers from the University of Cincinnati College of Medicine.

Sunil Verma, MD, MSEd, FRCPC, discusses evolving standards of early stage HER2-positive breast cancer.

Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, discusses the goals of the SystHERs Registry.

The favorable safety profile of T-DM1 (ado-trastuzumab emtansine; Kadcyla) makes it apt to be looked at in other settings of breast cancer, according to a large study published in the Journal of Clinical Oncology.

Ragene Rivera, MD, medical oncologist, Texas Oncology-El Paso Cancer Treatment Center, discusses the next treatment steps for a patient with HER2-negative chemotherapy-resistant metastatic breast cancer.

Linda D. Bosserman, MD, FACP, president, medical oncologist, Wilshire Oncology Medical Group, discusses how she determines if a patient is resistant to a taxane or anthracyclines.

Linda D. Bosserman, MD, FACP, president, medical oncologist, Wilshire Oncology Medical Group, discusses how she would treat a patient with HER2-negative metastatic breast cancer.

Ragene Rivera, MD, medical oncologist, Texas Oncology-El Paso Cancer Treatment Center, discusses how she decides between hormone therapies in patients with ER+/PR+ tumors.

Joyce A. O’Shaughnessy, MD, from Baylor Charles A. Sammons Cancer Center, discusses the results of a recent breast cancer study.

Robert L. Kirkman, MD, President and CEO, Oncothyreon, discusses the development of ONT-380, an oral HER2-specific inhibitor, for the treatment of patients with HER2-positive metastatic breast cancer.

Extended adjuvant treatment with neratinib (PB272, HKI-272) significantly improved disease-free survival (DFS) compared with placebo for patients with HER2-positive breast cancer who received prior adjuvant trastuzumab.

Sara Hurvitz, MD, medical oncologist, UCLA Medical Center, discusses patient outcomes associated with PIK3CA mutations.

Adam M. Brufsky, MD, PhD, discusses the results of a study that looked at the effect of prior trastuzumab on eribulin mesylate in combination with trastuzumab as first-line treatment for HER2-positive locally recurrent or MBC.

Sunil Verma, MD, MSEd, FRCPC, associate professor, University of Toronto, chair, Breast Medical Oncology, Sunnybrook Odette Cancer Centre, discusses targeting HER2 in patients with early-stage breast cancer.

Sunil Verma, MD, MSEd, FRCPC, associate professor, University of Toronto, chair, Breast Medical Oncology, Sunnybrook Odette Cancer Centre, comments on HER2 testing and the utility of Ki67.